Basel pharmaceutical supplier Lonza is further investing in its site in the canton of Aargau. A new commercial drug product fill and finish facility is to be built at the Stein site for completion in 2026, as was reported in a press release. The company is making an investment of half a billion francs.
The new facility will enable Lonza to provide customers with a complete and integrated end-to-end solution for the entire product lifecycle. With the new system, Lonza will not only produce active ingredients, but also be able to fill and package these on a large scale. Lonza can consequently deliver ready-to-use drugs.
“This strategic investment completes our offering in drug product and strengthens our position as a leading CDMO (contract manufacturer),” CEO Pierre-Alain Ruffieux said in the statement.
It was already known that Lonza wanted to expand in Stein, but so far there has been talk of investments totaling around 40 million francs. According to an article by SRF, the new facility is now expected to create 400 additional jobs rather than the initial 200 forecast.
The new flexible facility will be built on the same campus as Lonza’s current clinical drug product facility in Stein. Currently, 80 people work for Lonza here.
